ClinicalTrials.gg

Program

becotatug vedotin

Also written as “MRG003”, “MRG003+HX008” and “MRG003 + Pucotenlimab”.

Its studies are mostly in Squamous Cell Carcinoma of Head and Neck · Nasopharyngeal Carcinoma · Carcinoma, Non-Small-Cell Lung · Biliary Tract Neoplasms · Stomach Neoplasms, led by Lepu Biopharma.

Furthest: phase 3, since Feb 21, 202310 company-led studies, 5 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lepu Biopharma105 open or runningphase 3since Feb 21, 2023Apr 6, 2021Aug 2027phase 2 · NCT05688605

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 6, 2021First studies: 3 phase 2 studiesFirst studyNCT04838964, NCT04838548, NCT04868162
  2. Apr 29, 2021Phase 1 study in Advanced Solid TumorsNCT04868344 · 61 enrolled · China
  3. Nov 17, 2021Phase 2 study in RecurrenceNCT05126719 · 238 enrolled · China
  4. Jan 5, 2022Phase 2 study in Stomach NeoplasmsNCT05188209 · 6 enrolled · China
  5. Jan 6, 2023Phase 2 study in Advanced Solid TumorsNCT05688605 · 18 planned · China
  6. Feb 21, 2023Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT05751512 · 180 planned · China
  7. May 8, 2025Phase 3 study in RecurrenceNCT06976190 · 446 planned · China
  8. Apr 30, 2026Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07586124 · 80 planned · China

Ahead

  1. Aug 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT05688605
  2. Dec 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07586124
  3. Dec 2027Primary completion: phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT05751512
  4. May 2029Primary completion: phase 3 study in RecurrenceNCT06976190

TargetBeta

EGFR →read by rule
“An antibody-drug conjugate (ADC) consisting of becotatug, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR) ”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07586124Squamous Cell Carcinoma of Head and Neck · China2RecruitingDec 202780
NCT06976190Recurrence · China3RecruitingMay 2029446
NCT05751512Squamous Cell Carcinoma of Head and Neck · China3RecruitingDec 2027180
NCT05688605Advanced Solid Tumors · China2RecruitingAug 202718
NCT05188209Stomach Neoplasms · China2TerminatedOct 12, 20226
NCT05126719Recurrence · China2Active, not recruitingDec 30, 2024238
NCT04868344Advanced Solid Tumors · China1CompletedMar 29, 202161
NCT04868162Recurrence · China2CompletedJul 26, 202470
NCT04838548Carcinoma, Non-Small-Cell Lung · China2CompletedMar 27, 202387
NCT04838964Biliary Tract Neoplasms · China2CompletedOct 20, 202215

How it is read

Names in the registry

  • “MRG003”, 7 entries
  • “MRG003+HX008”, 1 entry
  • “MRG003 + Pucotenlimab”, 1 entry
  • “Becotatug Vedotin for Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.